Why the study?
Does trimetazidine improve outcomes in patients with cardiovascular disorders such as heart failure and peripheral artery disease?
Does trimetazidine improve outcomes in patients with cardiovascular disorders such as heart failure and peripheral artery disease?
This review summarizes the evidence and guidelines for trimetazidine in cardiovascular diseases, addressing the controversy between its cytoprotective benefits and side effects.
Answers are grounded in this paper and cite their sources.
Trimetazidine's net benefit remains uncertain amid efficacy controversies and Parkinsonian risks; leaves open need for updated RCTs.
Trimetazidine is a cytoprotective drug whose cardiovascular effectiveness, especially in patients with stable ischemic heart disease, has been the source of much controversy in recent years; some have gone so far as to treat the medication as a 'placebo drug' whose new side effects, such as Parkinsonian symptoms, outweigh its benefits. This article is an attempt to present the recent key studies, including meta-analyses, on the use of trimetazidine in chronic heart failure, also in patients with diabetes mellitus and arrhythmia, as well as in peripheral artery disease. This paper also includes the most recent European Society of Cardiology guidelines, including those of 2013, on the use of trimetazidine in cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Chruściel et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: